Human Recombinant GM-CSF (E. coli-expressed)

Granulocyte-macrophage colony-stimulating factor
Catalog #
78015_C
Granulocyte-macrophage colony-stimulating factor
From: 185 USD

Overview

Granulocyte-macrophage colony-stimulating factor (GM-CSF) promotes the proliferation and differentiation of hematopoietic progenitor cells and the generation of neutrophils, eosinophils, and macrophages. In synergy with other cytokines such as stem cell factor, IL-3, erythropoietin, and thrombopoietin, it also stimulates erythroid and megakaryocyte progenitor cells (Barreda et al.). GM-CSF is produced by multiple cell types, including stromal cells, Paneth cells, macrophages, dendritic cells (DCs), endothelial cells, smooth muscle cells, fibroblasts, chondrocytes, and Th1 and Th17 T cells (Francisco-Cruz et al.). The receptor for GM-CSF (GM-CSFR) is composed of two subunits: the cytokine-specific α subunit (GMRα; CD116) and the common subunit βc (CD131) shared with IL-3 and IL-5 receptors (Broughton et al.). GM-CSFR is expressed on hematopoietic cells, including progenitor cells and immune cells, as well as non-hematopoietic cells. Recombinant human GM-CSF (rhGM-CSF) promotes the production of myeloid cells of the granulocytic (neutrophils, eosinophils and basophils) and monocytic lineages in vivo. It has been tested for mobilization of hematopoietic progenitor cells and for treating chemotherapy-induced neutropenia in patients. GM-CSF is able to stimulate the development of DCs that ingest, process, and present antigens to the immune system (Francisco-Cruz et al.).
Subtype
Cytokines
Alternative Names
Colony-stimulating factor 2, CSF-2, MGI-1GM, Pluripoitin-alpha
Cell Type
Dendritic Cells, Hematopoietic Stem and Progenitor Cells, Mesoderm, PSC-Derived, Monocytes, Myeloid Cells
Species
Human
Area of Interest
Immunology, Stem Cell Biology
Molecular Weight
14.6 kDa
Purity
≥ 95%

Related Products

Scientific Resources

Product Documentation

Document Type Product Name Catalog # Lot # Language
Document Type
Product Information Sheet
Product Name
Human Recombinant GM-CSF (E. coli-expressed)
Catalog #
78015, 78015.1, 78015.2, 78015.3
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
Human Recombinant GM-CSF (E. coli-expressed)
Catalog #
78015, 78015.1, 78015.2, 78015.3
Lot #
All
Language
English

Educational Materials(3)

Brochure
Tools For Your Immunology Research
Brochure
Cytokines, Chemokines and Growth Factors
Wallchart
Human Immune Cytokines

Product Applications

Data and Publications

Data

(A) The biological activity of Human Recombinant GM-CSF was tested by its ability to promote the proliferation of TF-1 cells. Cell proliferation was measured after 48 hours of culture using a fluorometric assay method. The EC50 is defined as the effective concentration of the growth factor at which cell proliferation is at 50% of maximum. The EC50 in the above example is 0.08 - 0.12 ng/mL.
(B) 1 μg of Human Recombinant GM-CSF was resolved with SDS-PAGE under reducing (+) and non-reducing (-) conditions and visualized by Coomassie Blue staining. Human Recombinant GM-CSF has a predicted molecular mass of 14.6 kDa.

Publications (1)

Nature communications 2014 jul Direct induction of haematoendothelial programs in human pluripotent stem cells by transcriptional regulators. I. Elcheva et al.

Abstract

Advancing pluripotent stem cell technologies for modelling haematopoietic stem cell development and blood therapies requires identifying key regulators of haematopoietic commitment from human pluripotent stem cells (hPSCs). Here, by screening the effect of 27 candidate factors, we reveal two groups of transcriptional regulators capable of inducing distinct haematopoietic programs from hPSCs: pan-myeloid (ETV2 and GATA2) and erythro-megakaryocytic (GATA2 and TAL1). In both cases, these transcription factors directly convert hPSCs to endothelium, which subsequently transform into blood cells with pan-myeloid or erythro-megakaryocytic potential. These data demonstrate that two distinct genetic programs regulate the haematopoietic development from hPSCs and that both of these programs specify hPSCs directly to haemogenic endothelial cells. In addition, this study provides a novel method for the efficient induction of blood and endothelial cells from hPSCs via the overexpression of modified mRNA for the selected transcription factors.
View All Publications

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.